Tissue Regenix appoints CEO

Writer, Stock Market Wire
Thursday, November 2, 2017 - 09:06

Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the group, effective immediately.

Couldwell has been a non- executive director since July 2013.

He has over 25 years' experience in the pharmaceutical and medical device industry and was most recently chief operating officer for Global Sanofi Biosurgery.

Prior to this he held a number of roles at Smith & Nephew including president, orthopaedics, Europe and senior VP sales and marketing of the advanced wound management business.

At 9:06am: (LON:TRX) Tissue Regenix Group PLC share price was 0p at 8.63p


Related content

Tissue Regenix secures additional coverage in the US for DermaPure

Tissue Regenix secured additional coverage with a US Group Purchasing Organization (GPO) for the use of DermaPure, a decellularized allograft dermis.

The company said the...

Thu, 04/04/2019 - 07:48


Tissue Regenix moves closer to profitability after revenue jumps

Regenerative medical devices company Tissue Regenix Group said it expected to move closer to its goal of generating 'sustainable profitability' in 2019 after it more...

Mon, 04/02/2019 - 14:17


Tissue Regenix signs European distribution agreement with Arthrex

Regenerative medical devices company Tissue Regenix Group said it had entered into an agreement allowing Arthrex to distribute its BioRinse bone portfolio throughout Europe, with...

Tue, 13/11/2018 - 09:19


Tissue Regenix confirms new CFO appointment

Manchester-based medical devices company Tissue Regenix Group confirmed that Gareth Jones had officially taken up the role of chief financial officer.

His appointment had been...

Mon, 29/10/2018 - 07:54


Tissue Regenix posts loss as costs offset higher revenue

Regenerative medical devices company Tissue Regenix Group posted a first-half loss, as higher revenue was offset by costs.

Pre-tax losses for the six months through...

Mon, 03/09/2018 - 09:21